Transcriptomic profiles and 5-year results from the randomized cll14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

HIGHLIGHTS

• who: Othman Al-Sawaf from the Study design and participants This phase, randomized, open-label, parallel-group registrational study was conducted at , sites in , countries (Supplementary Table, )The study was approved by the Central Ethics Committee of the University of Cologne, Germany. Patients were enrolled between , August , and , August, . The study was registered at US and EU clinical trial registries (NCT02242942, EudraCT, ) and approved by ethical review boards responsible for each study site. The study was performed according to the principles of the Declaration of Helsinki. All patients provided written informed consent to participate. The study protocol . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.